Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer – Pipeline Review, H2 2016, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 35, 3, 155 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 46 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Actinium Pharmaceuticals Inc
Adamed Sp z oo
Adgero Biopharmaceuticals Inc
Advanced Cancer Therapeutics
Advanced Proteome Therapeutics Corp
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Affimed GmbH
Agenus Inc
AGV Discovery SAS
AIMM Therapeutics BV
Almac Discovery Ltd
Ambrx Inc
Anavex Life Sciences Corp
AndroScience Corp
Aphios Corp
Aposense Ltd
Aptose Biosciences Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
BCN Biosciences LLC
Bio-Path Holdings Inc
BioCancell Ltd
Biogazelle NV
Bioncotech Therapeutics SL
Blirt SA
Boehringer Ingelheim GmbH
Can-Fite BioPharma Ltd
Celprogen Inc
Chiome Bioscience Inc
Cyclacel Pharmaceuticals Inc
CytomX Therapeutics Inc
Cytune Pharma SAS
CZ BioMed Corp
Daiichi Sankyo Company Ltd
DEKK-TEC Inc
Eli Lilly and Company
EntreChem SL
EnzymeBioSystems
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
GlycaNova Norway AS
GlycoMimetics Inc
Grunenthal GmbH
Halozyme Therapeutics Inc
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
Helix BioPharma Corp
Histogen Inc
Horizon Pharma Plc
Idera Pharmaceuticals Inc
Immune Pharmaceuticals Inc
Immunome Inc
Immunomedics Inc
Immunotope Inc
Immupharma Plc
IMPACT Therapeutics Inc
Incuron LLC
Infinity Pharmaceuticals Inc
Inflection Biosciences Ltd
Innopharmax Inc
Intezyne Technologies Inc
Ironwood Pharmaceuticals Inc
Jasco Pharmaceuticals LLC
Jiangsu Kanion Pharmaceutical Co Ltd
JW Pharmaceutical Corp
Karyopharm Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
Les Laboratoires Servier SAS
Lipocure Ltd
Lupin Ltd
Lymphocyte Activation Technologies SA
MabVax Therapeutics Holdings Inc
MacroGenics Inc
MaxiVAX SA
Meabco A/S
Medicenna Therapeutics Inc
Microlin Bio, Inc.
Molecular Targeting Technologies Inc
MolMed SpA
Monopar Therapeutics LLC
Multimmune GmbH
NormOxys Inc
Northwest Biotherapeutics Inc
Novartis AG
Omeros Corp
Omnitura Therapeutics Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Orega Biotech SAS
OSE Immunotherapeutics
Panacea Pharmaceuticals Inc
Patrys Ltd
PharmaCyte Biotech Inc
Pharminox Ltd
Philogen SpA
Pique Therapeutics
Plexxikon Inc
ProNAi Therapeutics Inc
Provecs Medical GmbH
Provectus Biopharmaceuticals Inc
Qu Biologics Inc
Recce Pty Ltd
Rexahn Pharmaceuticals Inc
Rgenix Inc
Sareum Holdings Plc
Savoy Pharmaceuticals Inc
Sellas Inc
Sigma-Tau SpA
Sirnaomics Inc
SOM Biotech SL
Somantix BV
Sorrento Therapeutics Inc
Sphaera Pharma Pvt Ltd
Starpharma Holdings Ltd
Sunshine Biopharma Inc
Synergys Biotherapeutics Inc
TaiRx Inc
Taiwan Liposome Company Ltd
Takis Srl
Targovax ASA
Transgene Biotek Ltd
TVAX Biomedical Inc
Tyg Oncology Ltd
TyrNovo Ltd
Vaccinogen Inc
Vault Pharma Inc
Vaxenta Biotechnologies
Vaximm AG
VG Life Sciences Inc
Yakult Honsha Co Ltd
Zensun (Shanghai) Sci & Tech Co Ltd
ZIOPHARM Oncology Inc